Recent 8-K filings for SCYX

• May 29, 2026, 4:01 PM ET other materiality 0.50 neutral item 5.03item 9.01 ◈ Governance Changes

  SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M

  Effective May 29, 2026, every 8 outstanding shares converted into 1 share; par value stays $0.001.

• May 22, 2026, 4:20 PM ET other material materiality 0.45 neutral item 5.07item 8.01

  SCYNEXIS stockholders approve 1-for-8 reverse stock split; effective May 29

  Reverse stock split approved at 1:8 ratio; authorized shares reduced from 150M to 18.75M.

• April 20, 2026, 7:59 PM ET leadership materiality 0.20 neutral item 5.02

  Director Steven C. Gilman to retire from SCYNEXIS Board at 2026 annual meeting

  Steven C. Gilman notified SCYNEXIS Board on April 16, 2026 of intent to retire and not stand for reelection.

• March 31, 2026, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 2.01item 7.01item 9.01 ◈ Material Agreements

  SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total

  Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.

• March 31, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 7.01item 8.01item 9.01 ◈ Material Agreements

  SCYNEXIS raises ~$40M in private placement; extends cash runway into mid-2029

  Gross proceeds of ~$40M from sale of 34.75M shares and 8.75M pre-funded warrants at $0.92 per unit; up to $52.2M additional if warrants exercised.

• March 31, 2026, 7:59 PM ET M&A materiality 0.30 neutral item 7.01item 9.01

  SCYNEXIS discusses asset acquisition in corporate update call

  Conference call held on March 31, 2026 covering an asset acquisition transaction.

• October 15, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01

  SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment

  Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.

• July 1, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  SCYNEXIS stockholders re-elect all seven directors, ratify Deloitte, approve say-on-pay at 2025 AGM

  All seven director nominees elected with >13M votes for each; broker non-votes ~12.5M.

• June 26, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  SCYNEXIS receives Nasdaq bid price deficiency notice; has until Dec 17 to regain compliance

  Received Nasdaq letter on June 20, 2025, for bid price <$1 for 30 consecutive business days.

• November 6, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  SCYNEXIS enters $50M at-the-market equity facility with Cantor Fitzgerald

  New Sales Agreement with Cantor allows sale of up to $50M of common stock at SCYNEXIS's option.

• September 10, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  SCYNEXIS updates corporate presentation; no material new details disclosed

  Filed 8-K on Sept 10, 2024 to announce updated investor slide deck.

• June 20, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

  SCYNEXIS stockholders elect all seven director nominees, approve equity plan and auditor at 2024 annual meeting

  All seven director nominees elected with 93.6%-96.7% of votes cast in favor.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.47 · Most common event other_material

1 positive 1 negative 10 neutral

source · SCYX on sec.gov